“Design And Development Of A Novel Formulation Of Pacritinib For Treatment Of Adults Intermediate And High Risk Myelofibrosis With Low Platelet Count”, Journal of Pharmaceutical Negative Results, pp. 649–652, Jan. 2023, doi: 10.47750/pnr.2023.14.S01.84.